2330 GMT - Fisher & Paykel Healthcare gains a bull in Citi, which thinks it offers investors both growth and reliable delivery. Citi expects "sustainable double-digit earnings growth in the midterm and lower exposure to consumer dynamics" from the medical-device maker than other healthcare stocks across Australia and New Zealand. It upgrades the stock to "buy" from "neutral." It raises its price target to NZ$51.00/share from NZ$40.00/share previously. The stock is down 1.3%, at NZ$43.37.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.